var data={"title":"Tisagenlecleucel: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tisagenlecleucel: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/815019?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tisagenlecleucel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tisagenlecleucel: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50552762\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytokine release syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving tisagenlecleucel. Do not administer tisagenlecleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurological toxicities:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurological toxicities, which may be severe or life-threatening, can occur following treatment with tisagenlecleucel, including concurrently with CRS. Monitor for neurological events after treatment with tisagenlecleucel. Provide supportive care as needed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50574572\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kymriah</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50552764\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD19;</li>\n      <li>\n        Antineoplastic Agent, CAR-T Immunotherapy;</li>\n      <li>\n        CAR-T Cell Immunotherapy;</li>\n      <li>\n        Cellular Immunotherapy, Autologous;</li>\n      <li>\n        Chimeric Antigen Receptor T-Cell Immunotherapy</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595200\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>For autologous use only; confirm patient identity prior to infusion.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (relapsed or refractory):</b> <b>Note:</b> A treatment course consists of lymphodepleting chemotherapy (with fludarabine and cyclophosphamide) followed by tisagenlecleucel 2 to 14 days following completion of the fludarabine/cyclophosphamide regimen. Actual number of CAR-positive T cells in tisagenlecleucel are provided in the certificate of analysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delay tisagenlecleucel infusion for unresolved serious adverse reactions from chemotherapy (eg, pulmonary/cardiac reactions or hypotension), or active uncontrolled infection, active graft versus host disease (GVHD), or increasing leukemia burden following lymphodepleting chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premedicate with acetaminophen and diphenhydramine (or another H<sub>1</sub>-antihistamine) ~30 to 60 minutes prior to tisagenlecleucel infusion. Do not use corticosteroids at any time (except for life-threatening situations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&lt;25 years and &le;50 kg:</b> IV: 0.2 to 5 x 10<sup>6</sup> CAR-positive viable T cells per kg body weight</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>&lt;25 years and &gt;50 kg:</b> IV: 0.1 to 2.5 x 10<sup>8</sup> CAR-positive viable T cells</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991374\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988722\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595201\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>For autologous use only; confirm patient identity prior to infusion.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (relapsed or refractory):</b> <b>Note:</b> A treatment course consists of lymphodepleting chemotherapy (with fludarabine and cyclophosphamide) followed by tisagenlecleucel 2 to 14 days following completion of the fludarabine/cyclophosphamide regimen. Actual number of CAR-positive T cells in tisagenlecleucel are provided in the certificate of analysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delay tisagenlecleucel infusion for unresolved serious adverse reactions from chemotherapy (eg, pulmonary/cardiac reactions or hypotension), or active uncontrolled infection, active graft versus host disease (GVHD), or increasing leukemia burden following lymphodepleting chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premedicate with acetaminophen and diphenhydramine (or another H<sub>1</sub>-antihistamine) ~30 to 60 minutes prior to tisagenlecleucel infusion. Do not use corticosteroids at any time (except for life-threatening situations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Children and Adolescents &le;50 kg:</b> IV: 0.2 to 5 x 10<sup>6</sup> CAR-positive viable T cells per kg body weight</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Children and Adolescents &gt;50 kg</b>: IV: 0.1 to 2.5 x 10<sup>8</sup> CAR-positive viable T cells</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220248\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220249\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595204\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cytokine release syndrome (CRS):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prodromal syndrome (low-grade fever, fatigue, anorexia):</i> Observe in person, exclude infection, administer antibiotics (per local guidelines) if neutropenic, manage symptomatically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Overt CRS (high fever, hypoxia, and/or mild hypotension):</i> Administer antipyretics, oxygen, IV fluids, and/or low-dose vasopressors as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe or life-threatening CRS (hemodynamic instability despite IV fluids and vasopressors, worsening respiratory distress [including pulmonary infiltrates, increasing oxygen requirement including high-flow oxygen and/or need for mechanical ventilation], rapid clinical deterioration):</i> Administer high-dose or multiple vasopressors, oxygen, mechanical ventilation and/or other supportive care as needed. Administer tocilizumab (patients &lt;30 kg: tocilizumab 12 mg/kg; patients &ge;30 kg: tocilizumab 8 mg/kg; maximum tocilizumab dose: 800 mg; see tocilizumab monograph).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Resistant CRS (no clinical improvement in 12 to 18 hours or worsening at any time despite proper management):</i> Administer multiple vasopressors, oxygen, mechanical ventilation and/or other supportive care as needed. Administer methylprednisolone 2 mg/kg initially, then 2 mg/kg/day until vasopressors and high-flow oxygen are no longer needed, then taper quickly. If no response to methylprednisolone within 24 hours, repeat tocilizumab dose. If no response to the second tocilizumab dose within 24 hours, consider a third tocilizumab dose or pursue alternative CRS management strategies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50574573\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kymriah:  (1 ea) [contains albumin human, dextran 40, dimethyl sulfoxide]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50574571\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595206\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For IV use only. Coordinate the timing of administration with thawing (may only be stored for up to 30 minutes at room temperature); infusion start time may need to be adjusted based on thawing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prime the tubing with NS prior to infusion. Infuse at a rate of 10 to 20 mL/minute, adjusting as appropriate for smaller children and smaller volumes. Infuse entire contents of bag (infusion bag volume ranges from 10 to 50 mL), then (while maintaining a closed tubing system) rinse infusion bag with 10 to 30 mL NS to assure as many cells as possible are infused. Do not use a lymphocyte depleting filter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to administration: Ensure tocilizumab and emergency equipment are available prior to infusion and during recovery period. Premedicate with acetaminophen and diphenhydramine (or other histamine-1 antihistamine) ~30 to 60 minutes prior to tisagenlecleucel infusion. Do not use corticosteroids at any time except in the case of life-threatening emergency. Confirm patient identity and match to patient identifiers (preceded by the letters &quot;DIN&quot; or &quot;Aph ID&quot;) on the infusion bag. Inspect the contents of the thawed infusion bag for visible cell clumps; if visible cell clumps remain, gently mix the contents of the bag (small clumps of cellular material should disperse with gentle manual mixing). Do not infuse if clumps are not dispersed, if the infusion bag is damaged or leaking, or if it otherwise appears to be compromised. Apply universal precautions for product handling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50552766\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia (relapsed or refractory):</b> Treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse in patients up to 25 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595169\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sound-alike/look-alike issues</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kymriah may be confused with Kynamro</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50580205\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (31%), tachycardia (26%), hypertension (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (37%), brain disease (34%), fatigue (22%), delirium (21%), anxiety (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (grades 3/4: 27%), hypophosphatemia (grades 3/4: 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (37%), diarrhea (26%), nausea (26%), vomiting (26%), constipation (18%), abdominal pain (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (100%), neutropenia (100%; grades 3/4: 40%, within 14 days after day 28; grades 3/4: 17%; within 14 days after day 56), thrombocytopenia (100%; grades 3/4: 27%; within 14 days after day 28; grades 3/4: 12% within 14 days after day 56), hypogammaglobulinemia (43%; grades &ge;3: 7%), febrile neutropenia (grades 3/4: 37%), hypofibrinogenemia (grades 3/4: 16%; with cytokine release syndrome), increased INR (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (grades 3/4: 28%), increased serum ALT (grades 3/4: 21%), increased serum bilirubin (grades 3/4: 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Cytokine release syndrome (79%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (41%; unknown pathogen), viral infection (26%), bacterial infection (19%), fungal infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (16%), myalgia (15%), arthralgia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoxia (24%), cough (19%), pulmonary edema (16%), tachypnea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (40%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial edema (10%), peripheral edema (10%), cardiac failure (7%), capillary leak syndrome (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (10%), seizure (3%), intracranial hemorrhage (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation (9%), hemophagocytic syndrome (7%), blood coagulation disorder (6%), prolonged partial thromboplastin time (6%), tumor lysis syndrome (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft versus host disease (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (10%), tremor (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (10%), pleural effusion (10%), respiratory distress (6%), respiratory failure (6%), respiratory distress syndrome (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Multi-organ failure (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation, aphasia, confusion, disorientation, impaired consciousness, mutism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50552767\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595190\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytokine release syndrome<b>: [US Boxed Warning]: </b><b>Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving tisagenlecleucel. Do not administer tisagenlecleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab. </b>Grade 3 or 4 CRS reactions have occurred. The median time to onset of CRS was 3 days (range: 1 to 22 days). Half of patients with CRS received tocilizumab; some patients required 2 or 3 doses of tocilizumab, and some patients required addition of corticosteroids (methylprednisolone). The median time to resolution of CRS was 8 days (range: 1 to 36 days). Key manifestations of CRS include high fever, lower than normal blood pressure, difficulty breathing, and may be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy. Risk factors for severe CRS are high pre-infusion tumor burden (&gt;50% blasts in bone marrow), uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy (fludarabine and cyclophosphamide), active infections, and/or inflammatory processes. Delay tisagenlecleucel infusion after lymphodepleting chemotherapy for unresolved serious adverse reactions from preceding chemotherapies (including pulmonary toxicity, cardiac toxicity, or hypotension), active uncontrolled infection, active graft versus host disease (GVHD), or worsening leukemia burden. Ensure that tocilizumab is available (a minimum of 2 doses) on site prior to tisagenlecleucel infusion. Monitor for signs or symptoms of CRS for at least 4 weeks after treatment<i>. </i>Patients should seek immediate medical attention if signs or symptoms of CRS occur at any time. Evaluate patients immediately at the first sign of CRS; hospitalize and begin supportive care, tocilizumab and/or corticosteroids as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytopenias: Prolonged cytopenias may occur several weeks after lymphodepleting chemotherapy and tisagenlecleucel infusion. Unresolved (by day 28 following tisagenlecleucel treatment) grade 3 and 4 cytopenias included neutropenia and thrombocytopenia; some patients still experienced grade 3 and 4 neutropenia or thrombocytopenia at 56 days post infusion. Prolonged neutropenia is associated with an increased risk of infection. Myeloid growth factors, particularly GM-CSF, are not recommended during the first 3 weeks after tisagenlecleucel infusion or until CRS has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B virus reactivation: Hepatitis B virus (HBV) reactivation (sometimes resulting in fulminant hepatitis, hepatic failure and death) can occur in patients treated with medications directed against B cells. Hepatitis has been reported in patients who are hepatitis B surface antigen (HBsAg) positive, and in patients who are HBsAg-negative but are hepatitis B core antibody (anti-HBc) positive. HBV reactivation has occurred in patients who appear to have resolved hepatitis B infection (HBsAg-negative, anti-HBc-positive and hepatitis B surface antibody [anti-HBs] positive). HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg-negative and anti-HBc-positive. Reactivation of HBV replication is often followed by hepatitis (increased transaminase levels). Increased bilirubin levels, liver failure, and death can occur in severe cases. Screen for HBV, HCV, and HIV in accordance with clinical guidelines prior to collection of cells for manufacturing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Allergic reactions may occur with tisagenlecleucel infusion. Serious hypersensitivity reactions, including anaphylaxis, may occur due to the dimethyl sulfoxide (DMSO) or dextran 40 components in tisagenlecleucel.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypogammaglobulinemia: Hypogammaglobulinemia and IgG agammaglobulinemia may occur in patients with a complete remission (CR) after tisagenlecleucel infusion. Because B-cell aplasia is an on-target effect of tisagenlecleucel, hypogammaglobulinemia may persist as long as tisagenlecleucel persists. Monitor immunoglobulin levels after tisagenlecleucel treatment. Manage hypogammaglobulinemia with infection precautions, antibiotic prophylaxis and immunoglobulin treatment (per standard replacement guidelines). Pregnant women who have received tisagenlecleucel may have hypogammaglobulinemia; assess immunoglobulin levels in newborns of mothers treated with tisagenlecleucel.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Serious infections (including life-threatening or fatal infections) occurred in patients after tisagenlecleucel infusion, including grades 3 and 4 infections. Viral, bacterial, and fungal infections were reported as well as infections due to unknown pathogens. Begin prophylaxis according to local guidelines prior to tisagenlecleucel infusion. Monitor for signs and symptoms of infection following treatment and manage appropriately. Neutropenic fever (grade 3 or 4) has been observed after tisagenlecleucel infusion and may occur concurrently with CRS. If neutropenic fever occurs, evaluate for infection and manage with broad spectrum antibiotics, fluids and other supportive care as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurological toxicities:<b> [US Boxed Warning]: </b><b>Neurological toxicities, which may be severe or life-threatening, can occur following treatment with tisagenlecleucel, and may occur concurrently with CRS. Monitor for neurological events after treatment and provide supportive care as needed. </b>Most neurological toxicities occurred within 8 weeks following tisagenlecleucel infusion and generally resolved within 12 days of onset. Grade 3 and 4 neurologic toxicities have been observed. The most common neurological toxicities were headache, encephalopathy, delirium, anxiety, and tremor; other manifestations included disturbances in consciousness, disorientation, confusion, agitation, seizures, mutism and aphasia. The onset of neurologic toxicity may be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Exclude other causes for neurological symptoms and manage supportively as needed. Due to the potential for neurologic events, including altered mental status or seizures, patients receiving tisagenlecleucel are at risk for altered or decreased consciousness or coordination in the 8 weeks following administration; during this initial period, advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Patients treated with tisagenlecleucel may develop secondary malignancies or leukemia recurrence. Monitor permanently for secondary malignancies. If a secondary malignancy occurs, contact the manufacturer (1-844-4KYMRIAH) to obtain patient sampling instructions for testing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of lymphodepleting chemotherapy, during tisagenlecleucel treatment, and until immune recovery following treatment. The safety of immunization with live viral vaccines during or following tisagenlecleucel treatment has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For autologous use only. Confirm patient identity and match to patient identifiers on the infusion bag prior to infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: [US Boxed Warning]: Tisagenlecleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Information is available at www.kymriah-rems.com or 1-844-4KYMRIAH.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50616393\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50616390\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114674&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Tisagenlecleucel. Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granulocyte Colony-Stimulating Factors: May enhance the adverse/toxic effect of Tisagenlecleucel.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: May enhance the adverse/toxic effect of Tisagenlecleucel.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Tisagenlecleucel may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595188\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. If placental transfer were to occur, fetal toxicity, including B-cell lymphocytopenia may occur.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy testing is recommended prior to therapy in sexually active women of reproductive potential. Refer to the cyclophosphamide and fludarabine monographs for information related to use of effective contraception in patients using these medications for lymphodepleting chemotherapy. The duration of contraception needed following tisagenlecleucel administration is not known. Pregnant women who have received tisagenlecleucel may have hypogammaglobulinemia; assess immunoglobulin levels in newborns of mothers treated with tisagenlecleucel.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595189\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tisagenlecleucel is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595208\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Screen for HBV, HCV, and HIV (prior to collection of cells for manufacturing). Monitor immunoglobulin levels (after treatment). Pregnancy testing (prior to therapy in sexually active females of reproductive potential).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for signs/symptoms of CRS for at least 4 weeks after treatment (evaluate immediately at the first sign of CRS), monitor for hypersensitivity reactions, neurologic toxicity, signs/symptoms of infection. Monitor (life-long) for secondary malignancies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595196\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy (containing human cells modified with a lentivirus) in which a patient's T cells are reprogrammed with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells. The CAR is comprised of a murine single-chain antibody fragment which recognizes CD19 and is fused to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta. CD3 zeta is a critical component for initiating T-cell activation and antitumor activity, while 4-1BB enhances expansion and persistence of tisagenlecleucel. After binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Tisagenlecleucel is prepared from the patient's peripheral blood cells obtained via leukapheresis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50595197\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: High distribution into bone marrow.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Tisagenlecleucel is present in blood and bone marrow and is measurable beyond 2 years.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Kymriah (tisagenlecleucel) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>N Engl J Med</i>. 2018;378(5):439-448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tisagenlecleucel-drug-information/abstract-text/29385370/pubmed\" target=\"_blank\" id=\"29385370\">29385370</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114674 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F50552762\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50574572\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50552764\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50595200\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991374\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988722\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50595201\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51220248\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51220249\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F50595204\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50574573\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50574571\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50595206\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50552766\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50595169\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50580205\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50552767\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50595190\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50616393\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50616390\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50595188\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50595189\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50595208\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50595196\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50595197\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/114674|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tisagenlecleucel-patient-drug-information\" class=\"drug drug_patient\">Tisagenlecleucel: Patient drug information</a></li></ul></div></div>","javascript":null}